2 completed, 2 terminated. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow LY2510924: new trials by email Literature Review of LY2510924 trials Research Report on LY2510924
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of LY2510924 and Durvalumab in Participants With Solid Tumors LY2510924, Durvalumab - Solid Tumor | Phase 1 | Terminated | Eli Lilly and Company | 9 | 2016-09-01 | 2019-08-12 |
| LY2510924, Idarubicin and Cytarabine in Patients With Relapsed or Refractory Acute Myeloid Leukemia LY2510924, Idarubicin, Cytarabine - Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 36 | 2016-05-09 | 2019-11-15 |
| A Study of LY2510924 in Participants With Extensive-Stage Small Cell Lung Carcinoma LY2510924, Carboplatin, Etoposide - Extensive Stage Small Cell Lung Carcinoma | Phase 2 | Completed | Eli Lilly and Company | 90 | 2011-09-01 | 2019-07-23 |
| A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma LY2510924, Sunitinib - Metastatic Clear Cell Renal Cell Carcinoma | Phase 2 | Terminated | Eli Lilly and Company | 110 | 2011-08-01 | 2019-07-23 |
Neoplasm Metastasis (2) · Neoplasms (2) · Clear-cell metastatic renal cell carcinoma (1) · Leukemia (1) · Leukemia, Myeloid, Acute (1) · Recurrence (1)
Eli Lilly and Company (3) · M.D. Anderson Cancer Center (1)
United States (3)